Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hoelzer

Showing results (391-400 of 415) with videos related to

Pageof 42
Sort By:
British Journal of Haematology|November 25, 2003
Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot studyO Rosen, H J Müller, N Gökbuget, et al.
Leukemia|November 15, 2014
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutationA A Mian, A Rafiei, I Haberbosch, et al.
Leukemia|September 16, 1998
High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemiaH Rieder, C Bonwetsch, L A Janssen, et al.
Der Internist|January 15, 2003
[Acute lymphatic leukemia in the adult. Diagnosis, risk groups and therapy]D Hoelzer, R Arnold, C R Bartram, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2002
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphomaM J Rummel, K U Chow, T Karakas, et al.
Onkologie|July 7, 2001
Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicineE Weidmann, S Boehrer, K U Chow, et al.
Annals of Hematology|February 9, 2000
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)A Ganser, G Heil, G Seipelt, et al.
Leukemia|January 11, 2012
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemiaH Pfeifer, T Lange, S Wystub, et al.
Blood Cancer Journal|June 28, 2014
FAT1 expression and mutations in adult acute lymphoblastic leukemiaM Neumann, M Seehawer, C Schlee, et al.
Leukemia|February 13, 2004
Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemiaM Brüggemann, V H J van der Velden, T Raff, et al.
Pageof 42

Showing results (391-400 of 415) with videos related to

Sort By:
Pageof 42
British Journal of Haematology|November 25, 2003
Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot studyO Rosen, H J Müller, N Gökbuget, et al.
Leukemia|November 15, 2014
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutationA A Mian, A Rafiei, I Haberbosch, et al.
Leukemia|September 16, 1998
High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemiaH Rieder, C Bonwetsch, L A Janssen, et al.
Der Internist|January 15, 2003
[Acute lymphatic leukemia in the adult. Diagnosis, risk groups and therapy]D Hoelzer, R Arnold, C R Bartram, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2002
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphomaM J Rummel, K U Chow, T Karakas, et al.
Onkologie|July 7, 2001
Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicineE Weidmann, S Boehrer, K U Chow, et al.
Annals of Hematology|February 9, 2000
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)A Ganser, G Heil, G Seipelt, et al.
Leukemia|January 11, 2012
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemiaH Pfeifer, T Lange, S Wystub, et al.
Blood Cancer Journal|June 28, 2014
FAT1 expression and mutations in adult acute lymphoblastic leukemiaM Neumann, M Seehawer, C Schlee, et al.
Leukemia|February 13, 2004
Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemiaM Brüggemann, V H J van der Velden, T Raff, et al.
Pageof 42